Northwire Canada EditionThursday, July 30, 2026
Sign inSubscribe
Northwire
⌕
ZAC 0.060 +0.0% ELE 21.18 −1.7% GHRT 0.750 +0.0% AEM 203.13 +0.1% JTWO 0.135 +0.0% EDR 10.63 −2.8% VMXX 0.750 +5.6% K 32.71 −1.5% AGI 40.13 −1.4% VGZ 2.40 +0.8% CAN 0.055 +0.0% NVO 0.055 +0.0% ARIS 19.57 −4.2% IVN 10.59 −0.8% MCI 0.165 +0.0% MTS 0.130 +0.0% ZAC 0.060 +0.0% ELE 21.18 −1.7% GHRT 0.750 +0.0% AEM 203.13 +0.1% JTWO 0.135 +0.0% EDR 10.63 −2.8% VMXX 0.750 +5.6% K 32.71 −1.5% AGI 40.13 −1.4% VGZ 2.40 +0.8% CAN 0.055 +0.0% NVO 0.055 +0.0% ARIS 19.57 −4.2% IVN 10.59 −0.8% MCI 0.165 +0.0% MTS 0.130 +0.0%
Production / Operations

Universal Ibogaine Provides Corporate Update

By The Northwire Desk — AI Analysis Oct 28, 2025 · 08:06 PSQ · 0.16 None
PSQ · Price

Executive Summary

  • Universal Ibogaine Inc. has temporarily closed its Kelburn Recovery Centre in Manitoba and laid off all staff as part of a broader restructuring effort.
  • The company is exploring financing options that could include the sale or lease of the Kelburn property to a third party.
  • UI continues to focus on advancing its clinical trial application for ibogaine treatment of opioid use disorder with Health Canada.

Key Details

  • Effective October 24, 2025, the Kelburn Recovery Centre ceased operations and all employees were terminated.
  • The closure is temporary while the company undertakes a restructuring that may involve various financing alternatives.
  • Potential disposition options for the Kelburn property include an outright sale or leasing arrangement to an external party.
  • No immediate financial impact (e.g., cash proceeds) was disclosed; the announcement is primarily operational and strategic in nature.
  • The company re‑affirms its primary focus on obtaining Health Canada approval for a clinical trial of ibogaine for opioid use disorder.
  • CEO Nick Karos is listed as the contact for further information.

Notable Quotes

“UI continues to focus on its main business, which is the effort to have Ibogaine approved for use under UI’s Clinical Trial Application which is planned to be submitted to Health Canada.” – Nick Karos, CEO

Materiality Assessment: Material – Negative (the temporary shutdown and staff layoffs represent a significant adverse operational development that could affect future revenue streams and stakeholder perception).

Read the original news release →